All In Biotech

Drug Trial Radar · NCT07508787

A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant

Phase 2b, Randomized, Multicenter, Double-Blind, Dose-Finding, Active-Controlled Study of Siplizumab (TCD601) Compared to Rabbit Anti-Thymocyte Globulin in Renal Transplant Recipients Requiring Induction Therapy and Receiving Standard of Care Immunosuppression With Tacrolimus, Mycophenolic Acid and Corticosteroids

Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Jun 29, 2026

Primary completion

Mar 28, 2028

Study completion Mar 28, 2028

Sponsor

Lead sponsor
ITB-Med LLCIndustry
Sponsor type
Industry
First posted
Apr 2, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if siplizumab can prevent rejection of a kidney transplant in adult participants with end stage kidney disease. The main questions it aims to answer are: How many adverse events do participants receiving two different doses of siplizumab have compared to rabbit anti-thymocyte globulin (rATG)? How many participants successfully keep their kidney transplant after receiving siplizumab or rATG? This will be calculated as those participants that did not: die; have their kidney fail to work properly (graft loss); their body rejects their transplant (tissue sample (biopsy)-proven acute rejection: BPAR); or who were lost to follow-up. How does the body respond to siplizumab after dosing at each of the 2 dose levels? How does siplizumab work in the body compared to rATG? Selected participants will be divided into 3 groups. In 2 of the groups, participants will be given siplizumab at one of the two study medicine doses. Participants in the third group will be given rATG. All participants will take the usual anti-rejection medicines given before, during, and after a kidney transplant. All participants will also be given medicines before the study drug to lower the risk of reactions, and medicines used to prevent or treat infections after the transplant. Participants will be asked to provide their medical history at the first visit at the study site where you will have your kidney transplant. At the first visit and other visits participants will be asked to provide their medication history, have a physical exam, check vital signs, have blood drawn for tests, and have non-invasive tests that record the electrical activity of your heart (ECG) and blood draws. Participants will be monitored for 12 months after transplant surgery.

Conditions

  • Renal Transplant Failure and Rejection

Interventions

  • SiplizumabDrug

    A non-agonistic, humanized, anti-CD2 monoclonal antibody of the IgG1κ class

  • Rabbit anti-thymocyte globulinDrug

    An anti-human thymocyte immunoglobulin preparation made of purified polyclonal antibodies derived from rabbits

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Assessment of the safety of 2 dose levels of siplizumab versus rATG.Time frame: 12 months

Locations

27 sites in 3 countries. Site status is shown where the registry gives one.

  • Keck Hospital of the University of Southern California

    Los Angeles, California · Recruiting

  • University of California - Los Angeles, Connie Frank Kidney Transplant Center

    Los Angeles, California · Recruiting

  • UC Davis Medical Center

    Sacramento, California · Recruiting

  • Tampa General Hospital

    Tampa, Florida · Recruiting

  • Emory University Hospital

    Atlanta, Georgia · Recruiting

  • University of Kansas Hospital

    Kansas City, Kansas · Recruiting

  • University of Kentucky Healthcare

    Lexington, Kentucky · Recruiting

  • Tulane Medical Center

    Metairie, Louisiana · Recruiting

  • UMass Chan Medical Center

    Worcester, Massachusetts · Recruiting

  • University of Michigan - Michigan Medicine

    Ann Arbor, Michigan · Recruiting

  • Henry Ford Health

    Detroit, Michigan · Recruiting

  • Cooperman Barnabus Medical Center

    Livingston, New Jersey · Recruiting

  • New York Presbyterian - Columbia University Irving Medical School

    New York, New York · Recruiting

  • New York Presbyterian - Weill Cornell Medical Center

    New York, New York · Recruiting

  • Duke University Medical Center

    Durham, North Carolina · Recruiting

  • University of Texas Southwestern Medical Center

    Dallas, Texas · Recruiting

  • Inova Fairfax Hospital

    Falls Church, Virginia · Recruiting

  • Virginia Commonwealth University Health

    Richmond, Virginia · Recruiting

  • University of Washington Medical Center

    Seattle, Washington · Recruiting

  • Santa Casa Demisericordia de Belo Horizonte

    Belo Horizonte, Minas Gerais, Brazil · Recruiting

  • Santa Casa de Misericordia de Porto Alegre - Hospital Dom Vincente Scherer

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Hospital de Clinicas de Porto Alegre

    Porto Alegre, Rio Grande do Sul, Brazil · Recruiting

  • Fundação Faculdade Regional de Medicina de São José do Rio Preto - Centro Integrado de Pesquisa

    São José do Rio Preto, São Paulo, Brazil · Recruiting

  • Fundação Oswaldo Ramos - Hospital do Rim (HRIM)

    São Paulo, São Paulo, Brazil · Recruiting

  • Hospital Universitari Vall D'Hebron

    Barcelona, Spain · Recruiting

  • Hospital Universitario Reina Sofía

    Córdoba, Spain · Recruiting

  • Hospital Universitario Regional de Malaga

    Málaga, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.